Recent Patent Filings for Tigecycline Injection
Tigecycline, a glycylcycline antibiotic used for complicated infections, has seen new patent activity focused on injectable formulations. In 2023, Accord Healthcare filed US Patent 11,617,698 for a tigecycline for injection composition with improved stability and reduced degradation, covering lyophilized powders with specific buffers and bulking agents.[1] This builds on earlier patents expiring around 2025-2027, aiming to extend protection amid generic competition.
When Do Original Tigecycline Patents Expire?
The core Tygacil (tigecycline) patents from Wyeth/Pfizer expired in the US by 2022, with pediatric exclusivity ending December 2023. Key formulation patents, like US 6,872,724 for injectable compositions, lapsed in 2022. DrugPatentWatch tracks 15 patents listed for Tygacil, with the last expiring in 2032—mostly method-of-use claims rather than core injection tech.[2] This opens doors for generics, but new secondary patents challenge that timeline.
Generic and Biosimilar Approvals for Injectable Tigecycline
FDA approved the first generic tigecycline for injection in December 2023 from Sandoz, matching Pfizer's Tygacil labeling for IV use in skin, intra-abdominal, and pneumonia infections.[3] Additional ANDAs from Accord, Apotex, and Dr. Reddy's are pending Paragraph IV challenges. No true biosimilars exist, as tigecycline is a small-molecule synthetic antibiotic, not biologic. Europe saw generics launch earlier via EMA in 2022.
Challenges to Tigecycline Injection Patents
Pfizer faces multiple Paragraph IV litigations. In 2023, Apotex challenged US 10,478,451 (a stability patent for injection), settled with a license allowing entry by 2026.[4] Accord's countersuits claim Pfizer's patents are invalid for obviousness in lyophilized formulations. These disputes delay full generic flooding, keeping prices high—branded Tygacil vials cost $1,000+ per treatment course versus generics at 20-30% less.
Formulation Improvements in New Patents
Latest patents emphasize injection-specific tweaks:
- Enhanced solubility via pH-adjusted buffers (e.g., glycine, sodium hydrogen phosphate) to cut reconstitution time.[1]
- Reduced impurities like epimer degradation, critical for hospital IV use.
- A 2024 Chinese patent (CN117018920) covers nanoparticle tigecycline injections for better bioavailability.[5]
These address clinical pain points like slow dissolution in standard 50mg/100mg vials.
Who Makes Tigecycline for Injection Now?
| Manufacturer | Product Status | Key Markets |
|--------------|----------------|-------------|
| Pfizer (Tygacil) | Branded originator | Global |
| Sandoz/Novartis | First US generic (approved Dec 2023) | US, EU |
| Accord Healthcare | ANDA pending; new patent holder | US, India |
| Apotex | Licensed entry 2026 | US, Canada |
| Meitheal Pharmaceuticals | Authorized generic via Pfizer deal | US |
Pricing: Generics dropped US wholesale acquisition cost to ~$200/vial from $1,000.[6]
Supply Issues and Clinical Impact
Tigecycline shortages peaked in 2023 due to manufacturing halts at Pfizer's plants, resolved by mid-2024 with generic ramps.[7] New patents target this by improving shelf-life to 36 months. Clinically, advancements enable outpatient IV use, though resistance concerns persist— tigecycline retains utility against multidrug-resistant Acinetobacter.
[1] US Patent 11,617,698
[2] DrugPatentWatch: Tygacil Patents
[3] FDA Generic Approval Notice
[4] Court Docket: Apotex v. Pfizer
[5] CN Patent 117018920
[6] IQVIA Pricing Data 2024
[7] FDA Drug Shortages List